Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
77
resultados
Última actualización
11/06/2026 [07:05:00]
Resumen de: WO2025029797A1
Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.
Resumen de: WO2026112937A1
Relate to an isolated vNAR single domain antibody that specifically binds to SARS-CoV-2 nucleocapsid protein, and a process for preparing the same.This isolated vNAR single domain antibody are also included.
Resumen de: US20260151415A1
0000 Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.
Resumen de: US20260151414A1
0000 Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.
Resumen de: US20260152531A1
0000 Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.
Resumen de: US20260151476A1
0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
Resumen de: EP4751733A2
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
Resumen de: EP4751641A2
Disclosed are methods and devices for analyzing non-volatile organics in exhaled breath and other aerosols using various diagnostic tools that enable rapid, low cost point of care assays for several diseases including respiratory tract diseases such as COVID-19. The disclosed methods and systems selectively capture non-volatile organics in exhaled breath and other aerosols in a packed bed column. The non-volatile organics are eluted and samples are analysis using diagnostic devices including MALDI-TOFMS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.
Resumen de: WO2025022303A1
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.
Resumen de: US12643063B1
0000 The present development is a nanofilter, i.e. a filter material that comprises inorganic nanowires impregnated into a non-woven polymer or cloth fabric material. The nanofilter comprises a fabric infiltrated with a nanowire powder slurry selected from anatase titania (TiO<2>), zinc oxide (ZnO), silica, tin oxide, alumina (Al<2>O<3>), or combinations thereof. Exemplary fabrics include a non-woven polymer and a cotton fabric cloth. The nanowire powder slurry effectively produces a coating on the fabric. Optionally, the nanowires may be functionalized using nanoparticles and/or disinfecting salt particles. The infiltrated nanowires form a porous network with sub-micron scale openings and provide filtration of any airborne particles, liquid droplets and viruses including COVID 19. The nanofilter may be used in a variety of applications, such as a nanofilter respirator as described herein.
Resumen de: MX2026005926A
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Resumen de: CA3126560A1
A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,
Resumen de: US20260146062A1
0000 Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Resumen de: WO2026112441A1
The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo4.2.0octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzodazepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).
Resumen de: WO2026110758A1
Problem To provide a VHH which specifically binds to receptor binding domains of spike proteins of various types of variants of SARS-CoV2. Solution A VHH having any one or more of the characteristic properties mentioned below can recognize various types of variants of SARS-CoV2. (a) The VHH binds to Wuhan-Hu-1, delta variant, or micron variant of SARS-CoV2. (b) CDR1, CDR2, and CDR3 include the amino acid sequences represented by SEQ ID NOs: 1, 2, and 3, respectively; and/or (c) the VHH recognizes the amino acid sequence represented by SEQ ID NO: 4 and/or the amino acid sequence represented by SEQ ID NO: 5. This fusion protein which is obtained by fusing the VHH with ACE2 or an Fc form thereof enhances the SARS-CoV2 neutralizing capability and can be used in a pharmaceutical composition for treating or preventing COVID-19.
Resumen de: WO2026108766A1
Provided herein are live attenuated viruses for protection against respiratory syncytial virus (RSV) and/or coronavirus Sars-CoV-2. The live attenuated chimeric virus strains utilize a master backbone based on a live attenuated influenza virus (LAIV), which includes a deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1). These chimeric strains are engineered to express one or more antigens of RSV alone or in combination with Sars-CoV-2. The chimeric virus strain can protect a subject in need thereof against a challenge from any of RSV, Sars-CoV-2, influenza, or a combination thereof. This viral vector system offers an important strategy for developing highly attenuated and immunogenic live attenuated vaccines with the capacity to induce protective immunity against the three respiratory infections.
Resumen de: US20260144861A1
0000 This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.
Resumen de: AU2024395949A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Resumen de: US20260146077A1
0000 Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies. In some embodiments, the SARS-CoV-2 is the BA.4 or BA.5 variant.
Resumen de: ZA202301746B
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US12636282B1
Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.
Resumen de: WO2026106262A1
The present invention relates to a biomarker composition for diagnosing asthma caused by SARS-CoV-2 infection, and uses thereof. Through a change in the expression of CDHR3, SCGB3A2, PLAU, or NPY, which are biomarkers according to an embodiment of the present invention, it was confirmed that patients infected with SARS-CoV-2 have a higher incidence of asthma compared with healthy individuals, and thus the biomarker can be widely applied in the fields of diagnosis of SARS-CoV-2-induced asthma and drug screening.
Resumen de: US20260137677A1
0000 Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; M
Resumen de: US20260139001A1
Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (e.g., Omicron variants).
Nº publicación: US20260139062A1 21/05/2026
Solicitante:
INST OF SCIENCE TOKYO [JP]
INNATE CELL THERAPY INC [JP]
INSTITUTE OF SCIENCE TOKYO
INNATE CELL THERAPY INC.
Resumen de: US20260139062A1
The present invention provides a pharmaceutical composition for use in therapy or prevention of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19), the composition containing an IL-10 inhibitor.
BOPI
Sede Electrónica
